Robert W. Baird initiates coverage on Pharmasset (Nasdaq: VRUS) with a Neutral rating and a $21 price target.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE